Compare MLYS & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | VET |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2023 | 2004 |
| Metric | MLYS | VET |
|---|---|---|
| Price | $30.36 | $12.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $48.67 | $15.00 |
| AVG Volume (30 Days) | 998.0K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.07 |
| Revenue Next Year | N/A | $3.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.59 | $5.90 |
| 52 Week High | $47.65 | $14.82 |
| Indicator | MLYS | VET |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 44.01 |
| Support Level | $26.85 | $7.46 |
| Resistance Level | $31.19 | $14.55 |
| Average True Range (ATR) | 1.59 | 0.40 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 84.81 | 39.60 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.